Agoracom Blog Home

Author Archive

VIDEO – After Record Q3 and YTD Results, Datametrex $DM.ca $DTMXF Starts 2021 With 23,000 #COVID Test Sales To Film Industry For ~ $4M $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:34 PM on Thursday, January 14th, 2021

Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker. 

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:

  • Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
  • Record revenue of $4.9 million was generated in Q3
  • First ever positive EBIDTA quarter

If that wasn’t enough, they started off 2021 by announcing the following:

  • Sold over 23,000 onsite tests for the film industry at locations in Montreal, Toronto and Vancouver for the months of October through December 2020. This represents approximately $4,000,000 CAD in top-line revenue for Q4
  • Datametrex Providing COVID-19 Testing for Air Canada Front-Line and Inflight Employees
  • Binding LOI to acquire 100% of Concierge Medical Consultant Inc. a private telehealth and medical concierge services company currently generating revenue through a direct-to-consumer subscription model

Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.

Sheldon Inwentash $IDK.ca $IDKFF Discusses The Digitization Shock Happening In Canada And His Experience Investing In New Technologies $IP.ca $IPNFF $PKK.ca $PKKFF $MTRX $RACMF

Posted by AGORACOM-JC at 4:50 PM on Thursday, January 14th, 2021
IDK-square-for-blog

Entrepreneur Sheldon Inwentash is the founder and President of Toronto’s ThreeD Capital, a venture capital firm focused on investments in companies operating in junior resources, blockchain, artificial intelligence, psychedelics, electric vehicles and other sectors.

For Sheldon, a career that began in the life insurance industry as an oil and gas analyst quickly evolved into one that would include the creation of five companies and nine CEO roles, including a 20-year stay as the founder of Pinetree Capital.

In addition to providing companies with investment strategies, Sheldon provides counsel and guidance to C-suite executives. He has financed hundreds of public and private start-up companies, many of which went on to have successful exits.

We recently spoke with Sheldon about the digitization shock happening in Canada and his experience with investing in new technology.

During COVID, all you have to do is turn on the news to learn about the various digital strategies that companies have had to implement. Do you think digitization will continue to impact the way businesses operate, even after the pandemic is over?

Sheldon Inwentash: Yes. COVID definitely accelerated digitization, but I believe that whether there was a pandemic or not, we were going to see it happen. Even after COVID is over, people will be more embedded in working remotely and going through the digital mechanics. Whether it’s through a ZOOM call or shifting your business to eCommerce, my feeling is that we are in the midst of a digital acceleration, and this way of life will be with us indefinitely.

The stock market is at an all time high and junior cap stocks are on a tear. How do you think the digital revolution influenced this?

Sheldon Inwentash: There are a lot of digital technology stocks that are on the rise. There are also a lot of companies that, because of people having to purchase items online, have seen a sharp increase in stocks. I think the market is also discounting a pent-up demand on many fronts. Whether it’s the anticipation of airline stocks, oil and gas stocks, the green revolution – I think it’s a great time to be an investor because there are so many different verticals that are exciting and interesting to invest in. Frankly, I see this continuing over the long term.

ThreeD Capital invests in a range of industries, including blockchain technology, electric vehicles and AI. What about the future of technology piques your interest when it comes to making investment decisions?

Sheldon Inwentash: We have a number of disruptive technologies in our portfolio. These are technologies that change the way we do things or are different from what we’ve done before. They’re more efficient to use. Technology is an integral part of our investment philosophy and we are actively looking on a weekly basis at new emerging technology companies that we think have a chance for exponential growth.

A tech entrepreneur comes to you asking for capital. What do you expect from them in terms of a pitch?

Sheldon Inwentash: I want to hear a clear, concise message. From there, obviously, there’s depth of technology and infrastructure. Time is your enemy in this business. Even before we listen to a pitch, we prefer to get a PowerPoint presentation in advance because then we are able to determine whether or not it’s something that interests us. In some cases, even the PowerPoint isn’t so clear, but we may still be interested. In that case, we expect the founder to be able to communicate in a very succinct and fast matter or otherwise it tends to lose our focus.

What, in terms of venture capital, can investors do to help make Toronto the next Silicon Valley?

Sheldon Inwentash: I think Toronto is underrated in the amount of tech that I see evolving in the city. Anytime you have a number of universities and teaching and research centers within an hour outside of Toronto, which we do, those are the places that spawn all the R&D. Those are the places that come up with great new things.

People are leaving Silicon Valley. There are Silicon Valley’s in every city now because of the digital revolution. Anyone can work, from anywhere, whenever they want now. There’s really no barrier to entry.

In the blockchain space, Toronto is a global leader, but it’s not understood that that’s the case. The only thing that’s missing is capital, but there’s a lot of that in Toronto, as well, so there are opportunities everywhere. Arguably, Toronto doesn’t have to be a Silicon Valley of the north, but it does have its fair share of companies that are spawned here.

Source: https://www.finsmes.com/2021/01/threed-capital-interview-with-founder-chairman-and-ceo-sheldon-inwentash.html

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

AGORACOM Small Cap 60: Valeo Pharma $VPH.ca $VPHIF Discusses Health Canada Approval for Redesca™ and Redesca Hp™ $30 Million Forecasted Annual Peak Sales $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:14 PM on Thursday, January 14th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Commercial launch to impact first half 2021 revenue
  • $30 million forecasted annual peak sales
  • 8 years of proven in-market safety Internationally
  • Low molecular weight heparin increasingly used to prevent COVID-19 driven complications

“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly  being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.

Hub On AGORACOM / Corporate Profile

PlantX $VEGA.ca $PLTXF Announces Monthly Gross Revenue of $1,029,883 for December 2020 $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 8:37 AM on Thursday, January 14th, 2021

  • Announced that it achieved record monthly gross revenue of $1,029,883 for the month of December 2020.
  • November and December to the exceptional branding, marketing and partnerships that the Company has been able to establish over the past 12 months.
  • The revenue figures demonstrate the viability of the Company’s business model and its successful ability to reach its target consumer market.

VANCOUVER, British Columbia, Jan. 14, 2021  — PlantX Life Inc. (the “Company” or “PlantX”) (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce that it achieved record monthly gross revenue of $1,029,883 for the month of December 2020.

For the month of November 2020, the Company achieved gross revenue of approximately $640,000. The Company attributes the increased revenue between November and December to the exceptional branding, marketing and partnerships that the Company has been able to establish over the past 12 months. The revenue figures demonstrate the viability of the Company’s business model and its successful ability to reach its target consumer market.

“2020 has been a trying year for all of us, but our Company is seeing incredible growth and some of the benefits due to the stay-at-home environment. In December 2019, we had essentially zero sales revenue. To go from zero revenue per month to $1million in revenue a month is a huge feat and a massive milestone for the Company. I also want to bring up the incredible growth we’re seeing on a month-to-month basis growing 60% in December from November. The Company has some new marketing initiatives in store for 2021, and we’re excited to continue our success!’’ stated PlantX CEO Julia Frank.

Read More: https://agoracom.com/ir/PlantX/forums/discussion/topics/753007-plantx-announces-monthly-gross-revenue-of-1-029-883-for-december-2020/messages/2297841#message

3 Days After #Draganfly $DFLY.ca $DFLYF CEO Cam Chell Says “I’ll Build The Company Into One of The Top Three Drone Companies”, Company Announces #NASDAQ Intentions $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 8:04 AM on Thursday, January 14th, 2021

Most of us know drones as cool toys flying around the neighbourhood, or perhaps even as simple commercial applications for things like real estate videos. 

But the fact of the matter is that drone usage is about to go parabolic with huge corporations now testing ways to:

  • Use drones to provide Internet connections in remote locations. 
  • Use drones to collect crowd data.
  • ….. And there’s even a start-up that’s using drones to deliver tacos to your door.

In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones (hardware) to data … and one company is already ahead of the shift … DraganFly (DFLY: CSE) (DFLYF:OTCQB) (3U8:FSE)

DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:

  • Established in 1998 DFLY is considered the oldest commercial drone company in the world
  • Built the first drone that saved a life
    • Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
  • Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
  • Detect infectious conditions in a person from a distance of 190 feet
  • Conduct phenotyping, data collection and analysis by the USDA

Clients include:

  •  Ford
  • Warner Brothers
  • Suncor Energy
  • Shell
  • Redbull
  • Government of Canada 
    • Ontario Provincial Police, 
    • Australian Federal Police, 
    • Royal Canadian Mounted Police, 
    • Illinois State Police, 
    • Shell
    • Dow 

Most recently, DFLY’s Vital Intelligence technology was selected for implementation by Knightscope, a leader in a leader in autonomous robot security capabilities.  

With all of this under the Company’s belt, it’s easy to see why CEO Chell believes DFLY will become one of the top 3 drone companies in the world and why they have now begun the process of listing on NASDAQ.

If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or are just learning, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.

Loop Insights $MTRX $RACMF Enters UK Market With Pilot Agreement For Leading UK Pharmacy Solutions Provider, Servicing 12,000 Pharmacies Across United Kingdom $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca

Posted by AGORACOM-JC at 7:37 AM on Thursday, January 14th, 2021
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png
  • Announced the signing of a Pilot Agreement with PharmAssist Solutions to implement Loop’s analytics platform into multiple independent pharmacy affiliated locations.
  • Pharmassist is an independent pharmacy solutions provider that serves 15% of the UK market with 12,000 independent pharmacies.
  • Upon successful completion of the Pilot, it is the intention of both parties to implement Loop’s artificial intelligence-driven analytics platform across all 12,000 pharmacies in the United Kingdom.

VANCOUVER, British Columbia, Jan. 14, 2021 — Loop Insights Inc. (MTRX:TSXV)(RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated contact tracing to the brick and mortar space, is pleased to announce the signing of a Pilot Agreement with PharmAssist Solutions (“ Pharmassist ”) to implement Loop’s analytics platform into multiple independent pharmacy affiliated locations.

OPPORTUNITY FOR FULL IMPLEMENTATION ACROSS 12,000 LOCATIONS

Pharmassist is an independent pharmacy solutions provider that serves 15% of the UK market with 12,000 independent pharmacies. Upon successful completion of the Pilot, it is the intention of both parties to implement Loop’s artificial intelligence-driven analytics platform across all 12,000 pharmacies in the United Kingdom.

Pharmassist Managing Director Amar Randhawa stated, “Loop Insights data analytics solution is a game-changer for independent pharmacies here in the UK. PharmAssist Solutions has been integral to the success of the independent chain, and adding Loop’s ability to understand transaction details, shopping behaviors and habits, trends, and other powerful pieces of information once thought lost, will provide a massive benefit to each individual pharmacy. Understanding what products have been sold and prescribed gives these independents the ability to offer personal, relevant, and adjacent over the counter products to consumers, increasing sales, and delivering a more personal experience in-store. We are excited to be the first solutions provider in the UK market to offer this, and expect great uptake of the solution to our growing customer base.”

INSIGHTS REVENUE MODEL PROVIDES POTENTIAL FOR $USD 28.8 MILLION IN ANNUAL REVENUES UPON SUCCESSFUL COMPLETION OF PILOT

On November 4, 2020 , Loop announced it successfully completed a similar Pilot at 20 stores and was rolling out to all 550 retail locations of Your CBD Store . In that press release, the Company provided details with respect to its “Insights” pricing model including $USD 50 per month per till, with an average of 4 tills per retail location, which would equate to potential monthly recurring revenue of $USD 2,400,000 or $USD 28,800,000.

In addition, when the Company’s automated marketing “Engage” service and wallet pass loyalty applications are layered in, these numbers quickly multiply by 5-10x and provide the company with an even more significant potential revenue stream.

Loop Insights CEO Rob Anson stated, “Signing this Pilot with Pharmassist in the very early days of 2021 serves as a strong indication of Loop’s anticipated penetration into the UK and European markets. Coupled with our recently announced LOI to acquire Passcreator and take control of our technology in anticipation of major business developments in 2021, I can unequivocally say that Loop is heading into a major growth phase as promised in our letter to shareholders at the end of 2020.”

Read More: https://agoracom.com/ir/LoopInsights/forums/discussion/topics/752999-loop-insights-enters-uk-market-with-pilot-agreement-for-leading-uk-pharmacy-solutions-provider-servicing-12-000-pharmacies-across-united-kingdom/messages/2297830#message

$TGS.ca Announces $1 Million Strategic Financing $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 10:01 PM on Wednesday, January 13th, 2021
TGS Esports Announces Intent to Acquire Canadian Esports and Digital Media  Startup, Volcanic Media
  • Announced a non-brokered private placement consisting of the issuance of up to 5,555,555 units at a price of $0.18 per Unit for aggregate gross proceeds of $1,000,000
  • Each Unit is comprised of one common share and one non-transferrable common share purchase warrant

VANCOUVER, BC , Jan. 13, 2021 – TGS Esports Inc. (” TGS ” or the ” Company “) (TSXV: TGS) (FRA: 5RH) is pleased to announce a non-brokered private placement (the ” Offering “) consisting of the issuance of up to 5,555,555 units (each, a ” Unit “) at a price of $0.18 per Unit for aggregate gross proceeds of $1,000,000 . Each Unit is comprised of one common share (each, a ” Share “) and one non-transferrable common share purchase warrant (each, a ” Warrant “). Each Warrant will entitle the holder thereof to acquire one Share (each, a ” Warrant Share “) at a price of $0.25 per Warrant Share for a period of two years from closing of the Offering, subject to acceleration in the event that the Shares trade at or above $0.40 for ten consecutive trading days.

The proceeds from the Offering are expected to be used for general working capital. Insiders of the Company are leading participation in the Offering. Finder’s fees may be payable in connection with the Offering in accordance with the policies of the TSX Venture Exchange (the ” Exchange “).

Read More: https://agoracom.com/ir/TGSESports/forums/discussion/topics/752988-tgs-announces-1-million-strategic-financing/messages/2297794#message

VIDEO – PlantX Life $VEGA.ca $PLTXF Blasts Into 2021 With Plant-Based Expansion In USA, UK, Europe, Israel and #NASDAQ $BYND $TSN $CAG $FMCI $VERY $MEAT

Posted by AGORACOM-JC at 6:03 PM on Wednesday, January 13th, 2021

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.

PlantX Life (VEGA:CSE) (PLTXF:OTCQB) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community with the following:

  • Plant Based Meal Delivery (20 meals)
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

More than just talk, VEGA is already in full swing and growing FAST

  • Already Operating In Canada
  • US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
    • 6% Royalty Fee to PlantX on gross USA revenues
  • US Bricks & Mortar with San Diego flagship store opening in DECEMBER
  • £8 million Acquisition of Bloombox In The UK, generating millions in revenue
  • Closed $11.5M Non-Brokered Private Placement
  • · ….. and just announced its Application To List On NASDAQ

If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX Life Founder, Sean Dollinger.

You won’t just learn about a great small cap company, you’ll also learn how to live a healthier, tastier life.

CLIENT FEATURE: Valeo Pharma $VPH.ca $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:04 PM on Wednesday, January 13th, 2021

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Highlights of MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Click below to read in its entirety.

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.